MARKET

APRE

APRE

Aprea Therapeutics Inc
NASDAQ

Real-time Quotes | Nasdaq Last Sale

24.66
+0.18
+0.74%
After Hours: 24.66 0 0.00% 16:01 11/24 EST
OPEN
25.05
PREV CLOSE
24.48
HIGH
25.05
LOW
23.89
VOLUME
122.51K
TURNOVER
--
52 WEEK HIGH
53.11
52 WEEK LOW
19.67
MARKET CAP
522.47M
P/E (TTM)
-10.7451
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
Aprea Therapeutics to Participate in the 32nd Annual Piper Sandler Healthcare Conference
BOSTON, Nov. 19, 2020 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE), a biopharmaceutical company focused on developing and commercializing novel cancer therapeutics that reactivate the mutant tumor suppressor protein, p53, today announced that Christian S. Schade, Chairman and Chief Executive Officer, and Eyal Attar, M.D., Chief Medical Officer, will participate in a fireside chat at the virtual Piper Sandler Healthcare Conference being held December 1-3, 2020. The pre-recorded fireside chat will be accessible for a limited time beginning November 23, 2020 in the Investors section of Aprea Therapeutics’ website at www.aprea.com.About Aprea Therapeutics, Inc.Aprea Therapeutics, Inc. is a biopharmaceutical company headquartered in Boston, Massachusetts with research facilities in Stockholm, Sweden, focused on developing and commercializing novel cancer therapeutics that reactivate mutant tumor suppressor protein, p53. The Company’s lead product candidate is eprenetapopt (APR-246), a small molecule in clinical development for hematologic malignancies, including myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML). Eprenetapopt has received Breakthrough Therapy, Orphan Drug and Fast Track designations from the FDA for MDS, and Orphan Drug designation from the European Commission for MDS, AML and ovarian cancer. APR-548, a next generation small molecule reactivator of mutant p53, is being developed for oral administration. For more information, please visit the company website at www.aprea.com.The Company may use, and intends to use, its investor relations website at https://ir.aprea.com/ as a means of disclosing material nonpublic information and for complying with its disclosure obligations under Regulation FD.Forward-Looking Statement Certain information contained in this press release includes “forward-looking statements”, within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, related to our clinical trials, regulatory submissions and projected cash position. We may, in some cases use terms such as “predicts,” “believes,” “potential,” “continue,” “anticipates,” “estimates,” “expects,” “plans,” “intends,” “targeting,” “confidence,” “may,” “could,” “might,” “likely,” “will,” “should” or other words that convey uncertainty of the future events or outcomes to identify these forward-looking statements. Our forward-looking statements are based on current beliefs and expectations of our management team that involve risks, potential changes in circumstances, assumptions, and uncertainties. Any or all of the forward-looking statements may turn out to be wrong or be affected by inaccurate assumptions we might make or by known or unknown risks and uncertainties. These forward looking statements are subject to risks and uncertainties including risks related to the success and timing of our clinical trials or other studies, risks associated with the coronavirus pandemic and the other risks set forth in our filings with the U.S. Securities and Exchange Commission. For all these reasons, actual results and developments could be materially different from those expressed in or implied by our forward-looking statements. You are cautioned not to place undue reliance on these forward-looking statements, which are made only as of the date of this press release. We undertake no obligation to publicly update such forward-looking statements to reflect subsequent events or circumstances.Source: Aprea Therapeutics, Inc.Corporate Contacts:Scott M. Coiante Sr. Vice President and Chief Financial Officer 617-463-9385Gregory A. Korbel Vice President of Business Development 617-463-9385
GlobeNewswire · 5d ago
Aprea Therapeutics Q3 EPS $(0.58) Up From $(5.29) YoY
Aprea Therapeutics (NASDAQ:APRE) reported quarterly losses of $(0.58) per share. This is a 89.04 percent increase over losses of $(5.29) per share from the same period last year.
Benzinga · 11/05 22:46
Aprea Therapeutics EPS beats by $0.16
Aprea Therapeutics (APRE): Q3 GAAP EPS of -$0.58 beats by $0.16.Ccash and cash equivalents of $101.1M.Press Release
Seekingalpha · 11/05 22:28
Aprea Therapeutics to Highlight Changing Treatment Paradigm in MDS as well as Development Pipeline Progress at Virtual R&D Day Today
BOSTON, Oct. 30, 2020 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE), a biopharmaceutical company focused on developing and commercializing novel cancer therapeutics to reactivate mutant tumor suppressor protein, p53, will host a live virtual R&D Day Webinar, with presentations by key opinion leaders in hematology, today from 1:00 – 3:00 pm Eastern Time. R&D Day Webinar Agenda:1:00 pm – 2:00 pm: Introduction and discussion with Drs. David Sallman (Moffitt Cancer Center), Guillermo Garcia-Manero (MD Anderson Cancer Center), and Eyal Attar (Aprea’s Chief Medical Officer) to review current clinical therapy options for TP53 mutant MDS/AML patients and the potential role of eprenetapopt. Discussion with review of Aprea’s Phase 3 Clinical program in MDS to be followed by Q&A.2:00 pm – 2:15 pm: Overview of Aprea’s ongoing commercial preparations in front-line MDS by Greg Wessels, Aprea’s Chief Commercial Officer2:15 pm – 3:00 pm: Review of Aprea’s hematology and solid tumor clinical pipeline, by Dr. Eyal Attar followed by Q&A and Wrap-up.Virtual R&D Day Webinar InformationThe live webinar will begin at 1:00 pm Eastern Time and conclude at approximately 3:00 pm. Registration is accessible on the Events page of Aprea’s website. Following the webinar, a replay will be available for a limited time on Aprea’s website.About Aprea Therapeutics Aprea Therapeutics, Inc., (NASDAQ: APRE) is a biopharmaceutical company headquartered in Boston, Massachusetts with research facilities in Stockholm, Sweden, focused on developing and commercializing novel cancer therapeutics that reactivate the mutant tumor suppressor protein p53. The Company’s lead product candidate is eprenetapopt (APR-246), a small molecule in clinical development for hematologic malignancies, including myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML). Eprenetapopt has received Breakthrough Therapy, Orphan Drug and Fast Track designations from the FDA for MDS, and Orphan Drug designation from the European Commission for MDS, AML and ovarian cancer. APR-548, a next-generation small molecule reactivator of mutant p53, is being developed for oral administration. For more information, please visit the company website at www.aprea.com.The Company may use, and intends to use, its investor relations website at https://ir.aprea.com/ as a means of disclosing material nonpublic information and for complying with its disclosure obligations under Regulation FD.About p53, eprenetapopt and APR-548 The p53 tumor suppressor gene is the most frequently mutated gene in human cancer, occurring in approximately 50% of all human tumors. These mutations are often associated with resistance to anti-cancer drugs and poor overall survival, representing a major unmet medical need in the treatment of cancer.Eprenetapopt is a small molecule that has demonstrated reactivation of mutant and inactivated p53 protein – by restoring wild-type p53 conformation and function – and thereby induce programmed cell death in human cancer cells. Pre-clinical anti-tumor activity has been observed with eprenetapopt in a wide variety of solid and hematological cancers, including MDS, AML, and ovarian cancer, among others. Additionally, strong synergy has been seen with both traditional anti-cancer agents, such as chemotherapy, as well as newer mechanism-based anti-cancer drugs and immuno-oncology checkpoint inhibitors. In addition to pre-clinical testing, a Phase 1/2 clinical program with eprenetapopt has been completed, demonstrating a favorable safety profile and both biological and confirmed clinical responses in hematological malignancies and solid tumors with mutations in the TP53 gene.A pivotal Phase 3 clinical trial of eprenetapopt and azacitidine for frontline treatment of TP53 mutant MDS is ongoing. Eprenetapopt has received Breakthrough Therapy, Orphan Drug and Fast Track designations from the U.S. Food and Drug Administration for MDS, and Orphan Drug designation from the European Medicines Agency for MDS, AML and ovarian cancer.APR-548 is a next-generation small molecule p53 reactivator. APR-548 has demonstrated high oral bioavailability, enhanced potency relative to eprenetapopt in TP53 mutant cancer cell lines and has demonstrated in vivo tumor growth inhibition following oral dosing of tumor-bearing mice. A Phase 1 clinical trial of APR-548 in TP53 mutant MDS is planned.Forward-Looking StatementsCertain information contained in this press release includes “forward-looking statements”, within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, related to our clinical trials and regulatory submissions. We may, in some cases use terms such as “predicts,” “believes,” “potential,” “continue,” “anticipates,” “estimates,” “expects,” “plans,” “intends,” “may,” “could,” “might,” “likely,” “will,” “should” or other words that convey uncertainty of the future events or outcomes to identify these forward-looking statements. Our forward-looking statements are based on current beliefs and expectations of our management team that involve risks, potential changes in circumstances, assumptions, and uncertainties. Any or all of the forward-looking statements may turn out to be wrong or be affected by inaccurate assumptions we might make or by known or unknown risks and uncertainties. These forward-looking statements are subject to risks and uncertainties including risks related to the success and timing of our clinical trials or other studies and the other risks set forth in our filings with the U.S. Securities and Exchange Commission, including in our Quarterly Report on Form 10-Q for the quarter ended June 30, 2020. For all these reasons, actual results and developments could be materially different from those expressed in or implied by our forward-looking statements. You are cautioned not to place undue reliance on these forward-looking statements, which are made only as of the date of this press release. We undertake no obligation to publicly update such forward-looking statements to reflect subsequent events or circumstances. Corporate Contacts:Scott M. CoianteSr. Vice President and Chief Financial Officer617-463-9385 Gregory A. KorbelVice President of Business Development617-463-9385 Source: Aprea Therapeutics, Inc.
GlobeNewswire · 10/30 09:00
Aprea Therapeutics Launches Disease Awareness Website for Healthcare Professionals, p53reactivation.com
BOSTON, Oct. 14, 2020 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE), a biopharmaceutical company focused on developing and commercializing novel cancer therapeutics to reactivate mutant tumor suppressor protein, p53, today announced the launch of p53reactivation.com. The new website contributes to Aprea’s disease awareness initiative to educate healthcare professionals on the importance of p53 mutations in cancer and reactivation of mutant p53 as a potential therapeutic option for the treatment of cancer. “Mutations in p53 are present in approximately half of all cancers and are often associated with poor treatment outcomes and resistance to traditional anti-cancer therapies,” said Eyal Attar, M.D., Senior Vice President and Chief Medical Officer of Aprea Therapeutics. “Knowledge of the poor prognoses that accompany p53 mutations, the availability of diagnostic tests for their identification, and awareness of mutant p53 reactivation as a potential targeted therapeutic option, may collectively advance detection and treatment for cancer patients with this important and significant unmet medical need.”Corporate Contacts:Scott M. Coiante Sr. Vice President and Chief Financial Officer 617-463-9385Gregory A. Korbel Vice President of Business Development 617-463-9385Source: Aprea Therapeutics, Inc.
GlobeNewswire · 10/14 13:00
Aprea on go with early-stage study with APR-548 in blood disorder
The FDA has signed-off Phase 1 trial of Aprea Therapeutics's (APRE) APR-548 for the treatment of TP53 mutant myelodysplastic syndromes.APR-548 is a small molecule reactivator of mutant p53 that is being
Seekingalpha · 10/07 12:42
Aprea Therapeutics Receives FDA Approval to Initiate Phase 1 Clinical Studies for Next-Generation Mutant p53 Reactivator, APR-548
BOSTON, Oct. 07, 2020 (GLOBE NEWSWIRE) -- Aprea Therapeutics Inc., (NASDAQ:APRE), a clinical-stage biotechnology company focused on developing and commercializing novel cancer therapeutics that reactivate mutant p53
Benzinga · 10/07 12:02
Aprea Therapeutics Appoints Michael A. Kelly to Board of Directors
BOSTON, Sept. 29, 2020 (GLOBE NEWSWIRE) -- Aprea Therapeutics Inc., (NASDAQ: APRE), a clinical-stage biotechnology company focused on developing and commercializing novel cancer therapeutics that reactivate mutant p53 tumor suppressor protein, today announced the appointment of Michael A. Kelly to its
GlobeNewswire · 09/29 13:00
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of APRE. Analyze the recent business situations of Aprea Therapeutics Inc through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 5 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average APRE stock price target is 35.80 with a high estimate of 45.00 and a low estimate of 25.00.
EPS
Institutional Holdings
Institutions: 79
Institutional Holdings: 16.81M
% Owned: 79.36%
Shares Outstanding: 21.19M
TypeInstitutionsShares
Increased
23
707.17K
New
16
21.49K
Decreased
16
380.95K
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
-0.37%
Pharmaceuticals & Medical Research
0.00%
Key Executives
Chairman/President/Chief Executive Officer/Director
Christian Schade
Chief Financial Officer/Senior Vice President/Secretary
Scott Coiante
Senior Vice President/Chief Scientific Officer
Lars Abrahmsen
Senior Vice President
Eyal Attar
Vice President - Business Development
Gregory Korbel
Other
Gregory Wessels
Lead Director/Independent Director
John Henneman
Director
Michael Kelly
Director
Fouad Namouni
Director
Richard Peters
Independent Director
Johan Christenson
Independent Director
Guido Magni
Independent Director
Bernd Seizinger
  • Dividends
  • Splits
  • Insider Activity
No Data
Access Level 2 Advance
Nasdaq TotalView
for Free
Get Now
About APRE
Aprea Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing and commercializing cancer therapeutics that reactivate mutant p53 tumor suppressor protein. Its lead product candidate, APR-246, is a small molecule p53 reactivator that is being developed for hematologic malignancies, including myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML). APR-246 product candidate is designed to be administered intravenously and forms the active moiety, 2-methylene-quinuclidin-3-one (MQ), under physiological conditions. Its second product candidate, APR-548, is a p53 reactivator. APR-548 is being developed in an oral dosage form.
More
Hot Stocks
Symbol
Price
%Change

Webull offers kinds of Aprea Therapeutics Inc stock information, including NASDAQ:APRE real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, APRE stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading APRE stock methods without spending real money on the virtual paper trading platform.